Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Preparation and purification method and application of a kind of peptidomimetic compound

A compound and peptide technology, applied in the field of medicine, can solve problems such as inconvenient clinical administration of injections, joint swelling, anaphylactic shock, etc.

Active Publication Date: 2021-08-31
SHENZHEN WINKEY MEDICAL RES DEV
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in clinical use, Erigeron breviscapus injection also has a few rare side effects such as multiple organ dysfunction, anaphylactic shock, allergic asthma, abnormal liver function, and joint swelling.
Although the injection of scutellarin has a good clinical effect on cardiovascular diseases, the clinical administration of the injection is inconvenient and has rare side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation and purification method and application of a kind of peptidomimetic compound
  • Preparation and purification method and application of a kind of peptidomimetic compound
  • Preparation and purification method and application of a kind of peptidomimetic compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1 Anti-platelet peptidomimetic compound Scutellarin-HomoArg-Gly-Asp-Trp-NH 2 Synthesis

[0034] 1.1 Preparation of Fmoc-Linker-Amide Resin

[0035] Weigh 50 g (60 mmol) of Amide Resin resin into a 2L solid-phase synthesis reaction column. Wash the resin once with 400ml DMF, swell the resin with 500ml DCM for 20min, and remove the solvent. 400ml DMF washed the resin 3 times.

[0036] Weigh 80.9g (150mmol) of Fmoc-linker and 24.3g (180mmol) of HOBt into a dry 500ml wide-mouth Erlenmeyer flask. Add about 150ml of DMF solvent to dissolve and place in ice-water bath to cool for 2min, add DIC 30ml (195mmol) to activate for 3min, avoid water vapor. The activated amino acid was added to the swollen resin to react for 2 hours, and the reaction solution was sucked away. Wash the resin 3 times with 400ml DMF, 2min each time.

[0037] Join Ac 2 O 28ml (300mmol), DIPEA 10.7ml (60mmol), DMF 400ml mixed solution sealed for 3h, the resin was washed four times with DMF 50...

Embodiment 2

[0070] Example 2 Anti-platelet peptidomimetic compound Scutellarin-HomoArg-Gly-Asp-NH 2 Synthesis

[0071] 2.1 Preparation of Fmoc-Linker-Amide Resin

[0072] Weigh 50 g (60 mmol) of Amide Resin resin into a 2L solid-phase synthesis reaction column. Wash the resin once with 400ml DMF, swell the resin with 500ml DCM for 20min, and remove the solvent. The resin was washed three times with 400ml DMF.

[0073] Weigh 80.9g (150mmol) of Fmoc-linker and 24.3g (180mmol) of HOBt into a dry 500ml wide-mouth Erlenmeyer flask. Add about 150ml of DMF solvent to dissolve and place it in an ice-water bath to cool for 2 minutes, add 30ml of DIC (195mmol) to activate for 3 minutes, and avoid water vapor. The activated amino acid was added to the swollen resin to react for 2 hours, and the reaction solution was sucked away. Wash the resin 3 times with 400ml DMF, 2min each time.

[0074] Join Ac 2 O 28ml (300mmol), DIPEA 10.7ml (60mmol), DMF 400ml mixed solution sealed for 3h, the resin w...

Embodiment 3

[0102] Example 3 Anti-platelet peptidomimetic compound Scutellarin-HomoArg-Gly-Asp-Trp-Pro-NH 2 Synthesis

[0103] 3.1 Preparation of Fmoc-Linker-Amide Resin

[0104] Weigh 50 g (60 mmol) of Amide Resin resin into a 2L solid-phase synthesis reaction column. Wash the resin once with 400ml DMF, swell the resin with 500ml DCM for 20min, and remove the solvent. The resin was washed three times with 400ml DMF.

[0105] Weigh 80.9g (150mmol) of Fmoc-linker and 24.3g (180mmol) of HOBt into a dry 500ml wide-mouth Erlenmeyer flask. Add about 150ml of DMF solvent to dissolve and place it in an ice-water bath to cool for 2 minutes, add 30ml of DIC (195mmol) to activate for 3 minutes, and avoid water vapor. The activated amino acid was added to the swollen resin to react for 2 hours, and the reaction solution was sucked away. Wash the resin 3 times with 400ml DMF, 2min each time.

[0106] Join Ac 2 O 28ml (300mmol), DIPEA 10.7ml (60mmol), DMF 400ml mixed solution sealed for 3h, the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
wavelengthaaaaaaaaaa
Login to View More

Abstract

The invention discloses a class of anti-platelet aggregation peptidomimetic drugs and a preparation method and application thereof. This compound is a platelet GPIIb / IIIa receptor antagonist. It uses scutellarin, an active substance of traditional Chinese medicine, to modify the RGD peptide structure of GPⅡb / Ⅲa receptors, which can not only improve the GPⅡb / Ⅲa receptors of RGD peptides Specificity, but also improve the solubility of scutellarin. The compound has the pharmacological effect of anti-platelet aggregation, and can be used clinically to prevent myocardial oxygen supply artery occlusion, heart attack, unstable angina, no Q wave myocardial infarction, sudden death caused by coronary intervention, or can be used for acute coronary Syndrome patients.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to a peptidomimetic compound for anti-platelet aggregation, including its synthesis technology and screening method. The compound can be clinically used to prevent myocardial oxygen supply arterial occlusion, heart attack, unstable angina pectoris, non-Q wave myocardial infarction, sudden death caused by coronary intervention, or can be used for patients with acute coronary syndrome. Background technique [0002] Thrombotic disease is a common cardiovascular and cerebrovascular disease. It is a variety of diseases caused by the stenosis and occlusion of the blood vessel cavity caused by thrombus, which causes ischemia and infarction of major organs and causes dysfunction. It often manifests as myocardial infarction, ischemia, etc. Cerebral infarction and venous thromboembolism can affect various organs and systems of the body, and its morbidity, disability and mortality are high. [0003] In ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K5/09C07K5/11C07K7/06C07K1/04A61K38/06A61K38/07A61K38/08A61P7/02A61P9/00
CPCA61K38/00A61P7/02A61P9/00C07K5/0817C07K5/1019C07K7/06
Inventor 丁文锋
Owner SHENZHEN WINKEY MEDICAL RES DEV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com